...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Neuroimmunology: Official Bulletin of the Research Committee on Neuroimmunology of the World Federation of Neurology >Astilbin ameliorates experimental autoimmune myasthenia gravis by decreased Th17 cytokines and up-regulated T regulatory cells
【24h】

Astilbin ameliorates experimental autoimmune myasthenia gravis by decreased Th17 cytokines and up-regulated T regulatory cells

机译：Astilbin通过减少Th17细胞因子和上调T调节细胞改善实验性自身免疫性重症肌无力

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Astilbin, a major bioactive compound extracted from Rhizoma smilacis glabrae (RSG), has been reported to possess immunosuppressive properties. Our study first evaluated the effect of astilbin on experimental autoimmune myasthenia gravis (EAMG) in Lewis rats. The results showed that astilbin could attenuate the severity of EAMG by decreasing antigen-specific autoantibodies with up-regulation of regulatory T cells and down-regulation of Th17 cells. In addition to, astilbin also reduced the.efficiency of the antigen presenting cells on which the expression of MHC class II decreased. These results suggest that astilbin might be a candidate drug for immunoregulation of EAMG, and provide us new treatment ideas for human myasthenia gravis (MG). (C) 2016 Published by Elsevier B.V.
机译：据报道，从芦根（RSG）中提取的主要生物活性化合物曲霉菌具有免疫抑制特性。我们的研究首先评估了甜菜碱对Lewis大鼠实验性自身免疫性重症肌无力（EAMG）的影响。结果表明，曲霉菌素可通过上调调节性T细胞和下调Th17细胞来降低抗原特异性自身抗体，从而减轻EAMG的严重程度。此外，曲霉菌素还降低了II类MHC表达降低的抗原呈递细胞的效率。这些结果表明，曲霉毒素可能是EAMG免疫调节的候选药物，并为我们提供了重症肌无力（MG）治疗的新思路。 （C）2016由Elsevier B.V.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号